[Recommendations for the treatment of severe nosocomial pneumonia] (Q80972312)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

[Recommendations for the treatment of severe nosocomial pneumonia] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

R Jordà Marcos

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

A Torres Martí

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

F J Ariza Cardenal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

F Alvarez Lerma

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

F Barcenilla Gaite

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Comisión de Expertos del Grupo de Trabajo de Enfermedades Infecciosas de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Area de Trabajo de Tuberculosis e Infecciones Respiratorias de la Sociedad Española de Patología del Aparato Respiratorio

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Grupo de Estudio de Infección Hospitalaria de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

1 November 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

Archivos de Bronconeumologia

4 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

518-533

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Nosocomial pneumonia. A multivariate analysis of risk and prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia. Executive summary

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Diagnosis and treatment of nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Ventilator-associated pneumonia. European Task Force on ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Initial bacterial colonization in patients admitted to a respiratory intensive care unit: bacteriological pattern and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Survival in patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-associated Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

[Reccomendations for the diagnosis of pneumonia associated with mechanical ventilation]

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Prognostic Factors of Pneumonia Requiring Admission to the Intensive Care Unit

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Early onset pneumonia in neurosurgical intensive care unit patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Aetiology of pneumonia following isolated closed head injury

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Nosocomial pneumonia guidelines: an international perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Antimicrobial susceptibility of 1,422 Haemophilus influenzae isolates from respiratory tract infections in Spain. Results of a 1-year (1996-97) multicenter surveillance study. Spanish Surveillance Group for Respiratory Pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Empirical antimicrobial therapy of mechanically ventilated patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Single or multiple daily doses of aminoglycosides: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Aerosolized antibiotics in mechanically ventilated patients: delivery and response

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Drotrecogin Alfa (activated) Improves In-hospital and 90-day Survival in Patients With Severe Sepsis and Community-acquired Pneumoni

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

The high level resistance to carbapenems in Acinetobacter baumannii is a multifactorial problem

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Ventilator-associated pneumonia due to Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Monotherapy of nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

The role of nebulized antibiotics in treating serious respiratory infections

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Appropriate Antibiotic Treatment for Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Inhaled vancomycin-induced allergic reaction in decontamination of respiratory tracts for allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Trimethoprim-sulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Vancomycin and oxacillin synergy for methicillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Diagnosis of nosocomial pneumonia in mechanically ventilated patients by the blind protected telescoping catheter

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Bronchoscopy in nonresolving nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Nonresolving or slowly resolving pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Nonresolving pneumonia and mimics of pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

RecurrentPseudomonas aeruginosaPneumonia in Ventilated Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Recurrent Pseudomonas aeruginosa Pneumonia in an Intensive Care Unit

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Complications of nosocomial pneumonia in the surgical patient

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

A pharmacokinetic model-independent approach for estimating dose required to give desired steady-state trough concentrations of drug in plasma.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2804%2975583-0

7 January 2021

10.1016/S0300-2896(04)75583-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15530344%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference